Hemimegalencephaly Cell Models for Research

Hemimegalencephaly (HME) is a rare congenital malformation of cortical development characterized by unilateral enlargement of one cerebral hemisphere. The exact incidence is unknown but estimated at 1-3 per 1,000,000 live births (Orphanet, 2023). It is a leading cause of early-onset refractory epilepsy, often presenting in infancy with seizures that are resistant to antiepileptic drugs. According to the WHO, epilepsy affects about 50 million people globally, but HME accounts for a small fraction of pediatric cases. The condition is associated with significant developmental delay, hemiparesis, and cognitive impairment. Mortality is primarily due to complications from uncontrolled seizures, status epilepticus, or sudden unexpected death in epilepsy (SUDEP). There is no targeted therapy; treatment options include hemispherectomy, which can be curative for seizures but carries risks of neurological deficits. The 5-year survival for HME is not well-defined due to rarity, but studies suggest that with early surgical intervention, long-term survival can be favorable, though quality of life varies. Research into HME is critical due to its severity and the lack of effective pharmacological treatments.

HME serves as an excellent model for studying mTORopathies, a group of disorders caused by hyperactivation of the mechanistic target of rapamycin (mTOR) pathway. It shares molecular mechanisms with focal cortical dysplasia (FCD) and tuberous sclerosis complex (TSC). The disease is ideal for mechanistic studies because:

• • It exhibits clear genetic subtypes, primarily somatic mutations in genes such as AKT3, PIK3CA, MTOR, DEPDC5, TSC1, and TSC2.
• • Public datasets like ClinVar and COSMIC catalog mutations, enabling genotype-phenotype correlations.
• • Open questions include the role of somatic mosaicism, timing of mutations during neurodevelopment, and the contribution of different cell types (neurons vs. glia).
• • The disease offers a window into cortical development and neuronal migration, with potential implications for broader neurodevelopmental disorders.
• • Gene-edited cell models can recapitulate the mTOR pathway hyperactivation, facilitating drug screening and target validation.

HME is not a cancer but a developmental malformation; however, the molecular pathways involved overlap with oncogenic signaling. The major pathways are:

1. mTOR signaling pathway:

• • Activating mutations in AKT3, PIK3CA, MTOR, or loss-of-function mutations in DEPDC5, TSC1, TSC2 lead to constitutive mTORC1 activation.
• • This results in increased protein synthesis, cell growth, and proliferation, causing cytomegaly and dysmorphic neurons.

2. PI3K/AKT pathway:

• • Mutations in PIK3CA or AKT3 hyperactivate AKT, which in turn activates mTOR.
• • This pathway is critical for cell survival, growth, and metabolism.

3. GATOR1 complex (DEPDC5, NPRL2, NPRL3):

• • Loss-of-function mutations in DEPDC5 impair the GATOR1 complex, leading to mTORC1 activation.
• • This is a common cause of focal epilepsies and HME.

4. Wnt/β-catenin pathway:

• • Although less directly implicated, crosstalk with mTOR may contribute to aberrant cortical development.

The following table summarizes key genes and mutations associated with HME, based on data from ClinVar, COSMIC, and published literature. Frequencies are approximate and reflect somatic mutation prevalence in affected brain tissue.

Note: Frequencies are based on somatic mutations in brain tissue and may vary by cohort.

The primary deregulated network in HME is the mTOR pathway. Key nodes include:

• • mTORC1: Central regulator of cell growth; activated by AKT and inhibited by TSC1/TSC2.
• • AKT: Serine/threonine kinase that promotes cell survival and growth; activated by PI3K.
• • PI3K: Lipid kinase that generates PIP3, recruiting AKT to the membrane.
• • DEPDC5: Component of GATOR1, which inhibits mTORC1 in response to amino acid availability.
• • TSC1/TSC2: Form a complex that inhibits Rheb, a direct activator of mTORC1.
• • Rheb: Small GTPase that activates mTORC1 when bound to GTP.
• • S6K1 and 4E-BP1: Downstream effectors of mTORC1 that regulate protein synthesis.

Other networks with crosstalk include:

• • MAPK/ERK pathway: May be activated in some HME cases, contributing to cell proliferation.
• • Wnt/β-catenin pathway: Potential role in cortical development, though direct evidence is limited.
• • Apoptosis signaling: Dysregulated due to AKT activation, leading to survival of abnormal cells.

Several cell lines and organoid models have been used to study HME. The table below lists commonly used models, their origin, and key mutations.

Organoid advantages:

• • 3D structure mimics cortical architecture.
• • Can be derived from patient cells with somatic mutations.
• • Allow study of cell-cell interactions and migration.
• • Suitable for drug screening and CRISPR editing.

Animal models of HME include:

• • Genetically engineered mouse models (GEMMs):
• • Conditional knockout of Tsc1 or Tsc2 in neural progenitors.
• • Expression of mutant Akt3 or Pik3ca in developing cortex.
• • Depdc5 knockout mice.
• • Induced models:
• • In utero electroporation of mutant genes.
• • Viral delivery of CRISPR components to activate mTOR.
• • Patient-derived xenografts (PDX):
• • Rare due to non-neoplastic nature, but some studies use patient tissue transplanted into mice.

These models recapitulate key features such as enlarged hemispheres, seizures, and cytomegaly.

CRISPR-Cas9 technology enables the creation of isogenic cell lines that carry specific HME-associated mutations. These models are invaluable for studying disease mechanisms and drug responses. Examples include:

• • AKT3 p.E17K knock-in in human neural progenitor cells.
• • PIK3CA p.H1047R knock-in in iPSCs.
• • DEPDC5 knockout in HEK293T or neuroblastoma cells.
• • TSC1 knockout in induced pluripotent stem cells.

Commercially available, sequence-verified gene-edited cell models can accelerate research by providing consistent, validated tools. These models are engineered using CRISPR and are quality-controlled for genomic integrity and functional activity. They enable researchers to study the effects of specific mutations in a controlled genetic background, facilitating target validation and drug discovery.

Gene-edited cell models allow functional validation of mutations identified in HME patients. For example:

• • Knockout of DEPDC5 in neural cells leads to mTORC1 hyperactivation, confirming its role as a tumor suppressor.
• • Knock-in of AKT3 p.E17K increases cell size and proliferation, mimicking cytomegaly.
• • CRISPR screens can identify synthetic lethal interactions with mutant genes.

These studies help establish causality and uncover new therapeutic targets.

Isogenic pairs of cells (wild-type vs. mutant) are ideal for high-throughput drug screening. For HME, mTOR inhibitors such as rapamycin and everolimus are tested for efficacy. Gene-edited cells can model resistance mechanisms:

• • Mutations in MTOR that confer resistance to rapamycin.
• • Activation of compensatory pathways (e.g., MAPK) that bypass mTOR inhibition.
• • Screening of novel compounds that target downstream effectors.

These applications accelerate the development of precision therapies for HME.

CRISPR-based synthetic lethality screens in HME mutant cells can identify biomarkers for diagnosis or prognosis. For example:

• • Loss of DEPDC5 may sensitize cells to specific DNA damage agents.
• • AKT3 mutations may upregulate certain surface markers detectable in liquid biopsies.
• • Gene expression signatures from edited cells can be correlated with patient outcomes.

Such biomarkers could guide patient stratification and treatment monitoring.